Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -423.83% is 229% below its 5-year average of -128.71%, around the middle of its 5-year range (-4640.51%–8523.18%).
350.58% below its 12-month average of -94.06%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
-423.83%
GROSS MARGIN AVG TTM
-94.06%
GROSS MARGIN AVG 3Y
26.30%
GROSS MARGIN AVG 5Y
-128.71%
GROSS MARGIN AVG 10Y
-202.59%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-350.58%
CURRENT VS 3Y AVG
-1711.51%
CURRENT VS 5Y AVG
-229.29%
CURRENT VS 10Y AVG
-109.20%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 618 covered companies
CURRENT VS SECTOR MEDIAN
-1087.72%
vs the sector median at left
Seres Therapeutics, Inc.
Market Cap
$27.12M
Gross Margin
-423.83%
TTM Avg
-94.06%
3Y Avg
26.30%
5Y Avg
-128.71%
Market Cap
$28.73M
Gross Margin
-717.37%
TTM Avg
-308.69%
3Y Avg
-108.42%
5Y Avg
-83.18%
Market Cap
$29.52M
Gross Margin
-3398.93%
TTM Avg
-1699.46%
3Y Avg
-849.73%
5Y Avg
-566.49%
Market Cap
$24.59M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$24.30M
Gross Margin
0.00%
TTM Avg
49.92%
3Y Avg
18.04%
5Y Avg
44.48%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | $27.12M | -423.83% | -94.06% | 26.30% | -128.71% |
| InspireMD, Inc. (NSPR)vs › | $27.82M | 29.50% | 25.49% | 25.43% | 20.30% |
| aTyr Pharma, Inc. (ATYR)vs › | $28.73M | -717.37% | -308.69% | -108.42% | -83.18% |
| GridAI Technologies Corp. (GRDX)vs › | $29.52M | -3398.93% | -1699.46% | -849.73% | -566.49% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.59M | 0.00% | 0.00% | 0.00% | 0.00% |
| Kyntra Bio, Inc. (KYNB)vs › | $24.47M | 91.37% | 69.42% | 78.99% | 53.34% |
| CervoMed Inc. (CRVO)vs › | $29.81M | 0.00% | 0.00% | 0.00% | 0.00% |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.30M | 0.00% | 49.92% | 18.04% | 44.48% |
| BeyondSpring Inc. (BYSI)vs › | $30.51M | 0.00% | 0.00% | 25.00% | 50.00% |
| Context Therapeutics Inc. (CNTX)vs › | $30.63M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
-423.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | -118.16% |
| 2025-12-31 | 3251.83% |
| 2025-09-30 | -3703.99% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 63.00% |
| 2023-03-31 | 8523.18% |
| 2022-12-31 | -4640.51% |
| 2022-09-30 | -1151.92% |
| 2022-06-30 | -3513.08% |
| 2022-03-31 | -2555.66% |
| 2021-12-31 | -408.96% |
| 2021-09-30 | 68.53% |
| 2021-06-30 | -583.15% |
| 2021-03-31 | -412.47% |
| 2020-12-31 | -41.58% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | -175.94% |
| 2019-09-30 | -160.52% |
| 2019-06-30 | -42.89% |
| 2019-03-31 | -212.62% |
| 2018-12-31 | -133.01% |
| 2018-09-30 | -161.46% |
| 2018-06-30 | -421.53% |
| 2018-03-31 | -490.78% |
| 2017-12-31 | -686.71% |
| 2017-09-30 | 3.50% |
| 2017-06-30 | -665.10% |
| 2017-03-31 | -568.09% |
| 2016-12-31 | -567.19% |
| 2016-09-30 | -85.50% |
| 2016-06-30 | -638.15% |
| 2016-03-31 | -468.86% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 0.00% |
